Growing the love for investing
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Uses known Stock promoter RedChips to pump and dump.
Also has a Stage III cancer drug trial that will fail horribly. An amalgamation of 2 previous failed BIopharma companies.
http://www.cnbc.com/id/46300316
This is niche market. Only about 10% of breast cancer patients would be candidates to use this treatment. That said, the treatment is ongoing so they would be repeat "customers". The real question is will they find it effective in combination with hercepton? If it does improve outcomes then Roche wins because they just extended the patents with a "new" drug and obviously Gale wins.